Hypoxia-inducible factor 1A inhibition overcomes castration resistance of prostate tumors.
HIF1A
PTEN
castration-resistant prostate cancer
genetically-engineered mice
single-cell RNA sequencing
Journal
EMBO molecular medicine
ISSN: 1757-4684
Titre abrégé: EMBO Mol Med
Pays: England
ID NLM: 101487380
Informations de publication
Date de publication:
07 06 2023
07 06 2023
Historique:
revised:
17
03
2023
received:
21
11
2022
accepted:
20
03
2023
medline:
8
6
2023
pubmed:
19
4
2023
entrez:
18
4
2023
Statut:
ppublish
Résumé
Androgen deprivation therapy (ADT) is a cornerstone of prostate cancer (PCa) management. Although tumors initially regress, many progress to a hormone-independent state termed castration-resistant PCa (CRPC), for which treatment options are limited. We here report that the major luminal cell population in tumors of Pten
Identifiants
pubmed: 37070472
doi: 10.15252/emmm.202217209
pmc: PMC10245031
doi:
Substances chimiques
Androgen Antagonists
0
Receptors, Androgen
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e17209Informations de copyright
© 2023 The Authors. Published under the terms of the CC BY 4.0 license.
Références
Sci Rep. 2021 May 27;11(1):11210
pubmed: 34045601
Mol Cancer Ther. 2008 Jan;7(1):90-100
pubmed: 18202012
Ann Oncol. 2020 Sep;31(9):1119-1134
pubmed: 32593798
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Cancer Cell. 2011 Jun 14;19(6):792-804
pubmed: 21620777
Cancer Res. 2021 Nov 1;81(21):5477-5490
pubmed: 34301759
Cancer Cell. 2003 Sep;4(3):209-21
pubmed: 14522255
Sci Adv. 2022 Jul 22;8(29):eabo2295
pubmed: 35867798
Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2521-6
pubmed: 18268330
Nature. 2018 Jul;559(7714):363-369
pubmed: 29950727
Eur Urol. 2023 Mar;83(3):200-209
pubmed: 36243543
Nat Rev Urol. 2018 May;15(5):271-286
pubmed: 29460922
EMBO Mol Med. 2023 Jun 7;15(6):e17209
pubmed: 37070472
Immunity. 2014 Oct 16;41(4):518-28
pubmed: 25367569
Genomics. 1997 Jul 1;43(1):69-77
pubmed: 9226374
N Engl J Med. 2020 Dec 10;383(24):2345-2357
pubmed: 32955174
Nat Rev Urol. 2022 Apr;19(4):201-218
pubmed: 35079142
Cell Rep. 2018 Dec 18;25(12):3504-3518.e6
pubmed: 30566873
Int J Cancer. 2008 Nov 15;123(10):2430-7
pubmed: 18729192
Sci Adv. 2021 Jul 30;7(31):
pubmed: 34330705
Cancer Res. 2004 Mar 15;64(6):2270-305
pubmed: 15026373
Nat Cancer. 2022 Sep;3(9):1071-1087
pubmed: 36065066
Nat Rev Dis Primers. 2021 Feb 4;7(1):9
pubmed: 33542230
Science. 2022 May 27;376(6596):eabe1505
pubmed: 35617398
N Engl J Med. 2013 Jan 31;368(5):436-45
pubmed: 23363497
Eur Urol. 2013 Aug;64(2):260-5
pubmed: 23706522
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
Science. 2022 Sep 9;377(6611):1180-1191
pubmed: 35981096
Nat Biotechnol. 2018 Jun;36(5):411-420
pubmed: 29608179
Front Genet. 2020 Jan 17;10:1331
pubmed: 32010190
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Nat Protoc. 2016 Feb;11(2):347-58
pubmed: 26797458
Mol Endocrinol. 1993 Jan;7(1):23-36
pubmed: 8446105
Cell. 2014 Sep 25;159(1):163-175
pubmed: 25201529
Cell. 2015 Nov 5;163(4):1011-25
pubmed: 26544944
Cancer Cell. 2020 Aug 10;38(2):279-296.e9
pubmed: 32679108
Lancet Oncol. 2012 Oct;13(10):983-92
pubmed: 22995653
J Immunother Cancer. 2021 Jun;9(6):
pubmed: 34193566
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Cell. 2015 Jul 16;162(2):454
pubmed: 28843286
PLoS One. 2014 Feb 28;9(2):e90002
pubmed: 24587179